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We propose an innovative machine learning paradigm enabling precision medicine for prioritizing cognitive assessments ac-
cording to their relevance to Alzheimer’s disease at the individual patient level. The paradigm tailors the cognitive biomarker
discovery and cognitive assessment selection process to the brain morphometric characteristics of each individual patient.
We implement this paradigm using a newly developed learning-to-rank method PLTR. Our empirical study on the ADNI data
yields promising results to identify and prioritize individual-specific cognitive biomarkers as well as cognitive assessment
tasks based on the individual’s structural MRI data. The resulting top ranked cognitive biomarkers and assessment tasks
have the potential to aid personalized diagnosis and disease subtyping.
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1 INTRODUCTION
Identifying structural brain changes related to cognitive impairments is an important research topic in the study
of Alzheimer’s Disease (AD). Regression models have been widely investigated to predict cognitive outcomes
using morphometric measures extracted from structural magnetic resonance imaging (MRI) scans (e.g., [27]).
Such studies can improve the understanding of the neuroanatomical basis of cognitive impairments, but are not
designed to directly impact clinical practice. To bridge this gap, here we propose a new learning paradigmwhich
ranks cognitive assessments according to their relevance to AD using brain MRI data.
Cognitive assessments provide the most common clinical routine for the diagnosis of AD. Given a large num-
ber of cognitive assessment tools and a time-limited office visit, determining a proper set of cognitive tests is a
widely studied topic. Most existing studies aim to create selection guidelines for a targeted population [21]. In
this work, we propose a novel learning paradigm that embraces the concept of precision medicine and tailors the
cognitive test selection process to the individual characteristics of a given patient. Specifically, we perform an in-
novative application of a newly developed learning-to-rank method, denoted as PLTR [9], to the structural MRI
and cognitive assessment data of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort [25]. Using
structural MRI measures as the individual characteristics, we aim to not only identify individual-specific cog-
nitive biomarkers but also prioritize them and their corresponding assessment tasks according to AD-specific
abnormality.
The uniqueness of our study is twofold. First, traditional regression-based studies for prediction of cognitive
performances from MRI data focus on identifying relevant imaging biomarkers at the population level. The pro-
posed new model aims to identify AD-relevant cognitive biomarkers tailored to each individual patient. Second,
the identified cognitive biomarkers and assessments are prioritized based on the individual’s brain characteris-
tics, which can be used to guide the determination of cognitive assessments in a personalized fashion in clinical
practice. It has the potential to enable personalized diagnosis and disease subtyping.
2 LITERATURE REVIEW
2.1 Learning to Rank
Learning to Rank (LETOR) [16] is a popular technique used in recommender systems [10], web search [2] and
information retrieval [12]. Existing LETOR methods can be roughly classified into three categories [17]. The
first category is pointwise methods [6], in which a score function is learned to score individual instance, and
then instances are sorted/ranked based on their scores. The second category is pairwise methods [5], which
maximize the number of correctly ordered pairs to learn the ranking structure among instances. The last category
is listwise methods [11], in which a ranking function is learned to explicitly model the entire ranking. Generally,
pairwise and listwise methods have superior performance over pointwise methods due to their ability to leverage
order structure among instances in learning [17]. Recently, LETOR has also been used in drug discovery and
drug selection [13–15, 28]. For example, Agarwal et al. [1] developed a bipartite ranking method to prioritize
compounds. He et al. [9] developed a joint push and learning to rank method to select cancer drugs to patients.
These studies demonstrate the great potential of LETOR in computational biology and computational medicine.
2.2 Machine Learning for AD Biomarker Discovery
The importance of big data to enhance AD biomarker study has been widely recognized [25], resulting in nu-
merous data-driven machine learning models developed for early detection of AD and identification of relevant
biomarkers including cognitive measures. These models are often designed to accomplish tasks such as classifi-
cation (e.g., [24]), regression (e.g., [22, 26, 27]) or both (e.g., [4, 23]), where imaging and other biomarker data are
used to predict diagnostic, cognitive and/or other outcome(s) of interest. Although outcome-relevant biomark-
ers can be identified here, they are selected at the population level and not specific to any individual subject. To
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bridge this gap, we propose the PLTR method here for biomarker prioritization at the individual level, which
has the potential to impact personalized diagnosis.
3 MATERIALS
The imaging and cognitive data used here were obtained from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database [25]. The ADNI was launched in 2003 as a public-private partnership, led by Principal Inves-
tigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, other
biological markers, and clinical and neuropsychological assessment can be combined to measure the progres-
sion of mild cognitive impairment (MCI, a prodromal stage of AD) and early AD. For up-to-date information,
see www.adni-info.org.
Participants include 819 ADNI-1 subjects, including 229 healthy control (HC), 397 MCI and 193 AD partici-
pants. Combining MCI and AD subjects as patients, we have 590 cases and 229 controls. Baseline 1.5T MRI scans
and cognitive assessment data were downloaded from the ADNI website (adni.loni.usc.edu). MRI scans were
processed using Freesurfer version 5.1 as described in [19], where volumetric and cortical thickness measures
of 101 regions relevant to AD were extracted to characterize brain morphometry.
Our analysis focuses on 151 scores assessed in 15 neuropsychological tests. For convenience, we call these
measures as cognitive features and these tests as cognitive tasks. The 15 studied tasks include Alzheimer’s Disease
Assessment Scale (ADAS), Clinical Dementia Rating Scale (CDR), Functional Assessment Questionnaire (FAQ),
Geriatric Depression Scale (GDS), Mini-Mental State Exam (MMSE), Modified Hachinski Scale (MODHACH),
Neuropsychiatric Inventory Questionnaire (NPIQ), Boston Naming Test (BNT), ClockDrawing Test (CDT), Digit
Span Test (DSPAN), Digit Symbol Test (DSYM), Category Fluency Test (FLUENCY), Weschler’s Logical Memory
Scale (LOGMEM), Rey Auditory Verbal Learning Test (RAVLT) and Trail Making Test (TRAIL).
4 METHODS
4.1 Joint Push and Learning-To-Rank – PLTR
Weuse the joint push and learning-to-rankmethod as developed inHe et al. [9], denoted as PLTR, for personalized
cognitive feature prioritization. Our goal is to prioritize cognitive features for each patient that are most relevant
to his/her disease diagnosis using patients’ brain morphometric measures extracted from their MRI scans. In
specific, the cognitive features are in the form of scores or answers from cognitive tasks that the patients take.
The prioritization result can potentially be used in clinical practice to recommend the most relevant cognitive
features or tasks that can most effectively help diagnosis of an individual.
In the context of MCI/AD cognitive feature prioritization, PLTR learns and uses latent vectors of patients
and their imaging features to score each cognitive feature for each patient, and ranks the cognitive features
based on their scores; patients with similar imaging feature profiles will have similar latent vectors. During the
learning process, PLTR explicitly pushes the most relevant cognitive features on top of the less relevant ones
for each patient, and therefore optimizes the latent patient and cognitive feature vectors so they will reproduce
the pushed ranking structures. In PLTR, such latent vectors are learned by solving the following optimization
problem:
min
U ,V
Ls = (1 − α)P
↑
s + αO
+
s +
β
2
Ruv +
γ
2
Rcsim, (1)
where U = [u1, u2, · · · , um] and V = [v1, v2, · · · , vn] are the latent vector matrices for patients and features,
respectively; Ls is the overall loss function; and P
↑
s measures the average number of relevant cognitive features
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that are ranked below an irrelevant cognitive feature, defined as follows,
P
↑
s =
m∑
p=1
1
n+pn
−
p
∑
f −i ∈Pp
∑
f +j ∈P
+
p
I(sp(f
+
j ) ≤ sp (f
−
i )), (2)
wherem is the number of patients, f +j and f
−
i are the relevant and irrelevant features of patient Pp , n
+
p and n
−
p
are their respective numbers, and I(x) is the indicator function (I(x) = 1 if x is true, otherwise 0). In Problem (2),
sp (f i ) is a scoring function defined as follows,
sp (f i ) = u
T
pvi , (3)
that is, it calculates the score of feature f i on patient Pp using their respective latent vectors up and vi . In
Problem (1),O+s measures the ratio of mis-ordered feature pairs over the relevant features among all the patients,
defined as follows,
O+s =
m∑
p=1
1
|{ f +i ≻Pp f
+
j }|
∑
f +i ≻Pp f
+
j
I(sp(f
+
i ) < sp (f
+
j )), (4)
where f i ≻R f j represents that f i is ranked higher than f j under the relation R. In Problem (1), Ruv is a
regularizer on U and V to prevent overfitting, defined as Ruv =
1
m
‖U ‖2F +
1
n
‖V ‖2F , where ‖X ‖F is the Frobe-
nius norm of matrix X . Rcsim is a regularizer on patients to constrain patient latent vectors, defined as Rcsim =
1
m2
∑m
p=1
∑m
q=1wpq ‖up−uq ‖
2
2 , wherewpq is the similarity betweenPp andPq that is calculated using the imaging
features of the patients.
4.2 Joint Push and Learning-To-Rank with Hinge loss – PLTRh
The objective of PLTR is to score relevant features higher than less relevant features as shown in Equation 2
and Equation 4. However, in some cases, the score of relevant features is expected to be higher than that of less
relevant features by a large margin. For example, patients can be very sensitive to a few cognitive tasks but less
sensitive to many others. In order to incorporate such information, we propose a hinge loss based PLTR, denoted
as PLTRh. In PLTRh, the overall loss function is very similar to Equation 1, defined as follows,
min
U ,V
Lh = (1 − α)P
↑
h
+ αO+h +
β
2
Ruv +
γ
2
Rcsim, (5)
where Lh is the overall loss function; U , V , Ruv and Rcsim are identical as those in Equation 1. In PLTRh, P
↑
h
measures the average loss between the relevant features and irrelevant features using hinge loss as follows,
P
↑
h
=
m∑
p=1
1
n+pn
−
p
∑
f −i ∈Pp
∑
f +j ∈P
+
p
max(0, tp − (sp(f
+
j ) − sp (f
−
i ))), (6)
where max(0, tp − (sp(f
+
j ) − sp (f
−
i ))) is the hinge loss between the relevant feature f
+
j and the irrelevant feature
f −i , and tp is the pre-defined margin. Similarly, O
+
h
measures the average loss among the relevant features also
using hinge loss as follows,
O+h =
m∑
p=1
1
|{ f +i≻Ppf
+
j }|
∑
f +i ≻Pp f
+
j
max(0, to − (sp (f
+
i ) − sp (f
−
j ))), (7)
where to is also the pre-defined margin.
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5 DATA PROCESSING
5.1 Data Normalization
We selected all the MCI/AD patients from the dataset and did the following data normalization for the patients.
We first conducted a t-test on each of the cognitive features between patients and controls, and selected cognitive
features if there is a significant difference between patients and controls on these features. Then we converted
each of the selected features into [0, 1] by shifting and scaling the feature values. We also converted all the
normalized feature values based on the Cohen’s d of the features between patients and controls, so that smaller
values always indicate more AD possibility. After that, we filtered out features whose values are 0, 1 or 0.5 for
more than 95% patients, in order to remove features that are either extremely dominated by patients or controls,
or not discriminative. We conducted the same process as above on the imaging features.
5.2 Patient Similarities from Imaging Features
After the above normalization and filtering steps, we have 86 normalized imaging features remaining in the
study. We represent each patient as a vector of these features, denoted as rp = [rp1, rp2, · · · , rp86], where rpi
(i = 1, · · · , 86) is an imaging feature for patient p. We calculate the patient similarity from imaging features
using the radial basis function (RBF) kernel, that is, wpq = exp(−
‖rp−rq ‖
2
2σ 2 ), where wpq is the patient similarity
used in Rcsim.
6 EXPERIMENTAL PROTOCOL
6.1 Baseline Methods
We compare PLTR and PLTRhwith two baselinemethods: the BayesianMulti-TaskMulti-Kernel Learning (BMTMKL)
method [7] and the Kernelized Rank Learning (KRL) method [8].
6.1.1 Bayesian Multi-Task Multi-Kernel Learning (BMTMKL). BMTMKL is a strong baseline for biomarker prioriti-
zation. It was originally proposed to rank cell lines for drugs and won the DREAM 7 challenge 1. In our study,
BMTMKL uses the multi-task and multi-kernel learning within kernelized regression to predict amyloid feature
values and learns parameters by conducting Bayesian inference. We use the patient similarity matrix calculated
from FreeSurfer features as the kernels in BMTMKL.
6.1.2 Kernelized Rank Learning (KRL). KRL represents another strong baseline for biomarker prioritization. In
our study, KRL uses kernelized regression with a ranking loss to learn the ranking structure of patients and to
predict the amyloid feature values. The objective of KRL is to maximize the hits among the top k of the ranking
list. We use the patient similarity matrix calculated from FreeSurfer features as the kernels in KRL.
6.2 Training-Testing Data Splits
We test our methods in two settings: cross validation and leave-out validation. In the cross validation (CV), we
split the cognitive tasks for each patient into 5 folds. That is, all the features in a cognitive task will be either
split into training or testing set. We use 4 folds for training and the rest fold for testing, and do such experiments
5 times, each with one of the 5 folds as the testing set. The overall performance of the methods is averaged
out over the 5 testing sets. This setting corresponds to the goal to prioritize additional cognitive tasks that a
patient should complete. In the leave-out validation (LOV), we split patients into training and testing sets, such
that a certain patient and all his/her cognitive features will be either in the training set or in the testing set. This
corresponds to the use scenario to identify the most relevant cognitive tasks that a new patient needs to take,
1http://dreamchallenges.org/project/dream-7-nci-dream-drug-sensitivity-prediction-challenge/
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Fig. 1. Data split for cross validation (CV)
training patients testing patients
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Fig. 2. Data split for leave-out validation (LOV)
based on the existing imaging information of the patient, when the patient has not completed any cognitive
tasks. Figure 1 and Figure 2 demonstrate the CV and LOV data split processes, respectively.
6.3 Parameters
We conduct grid search to identify the best parameters for each model. We use 0.3 and 0.1 as the value of tp
and to , respectively. In the experimental results, we report the combinations of parameters that achieve the best
performance on evaluation metrics.
6.4 Evaluation Metrics
6.4.1 Metrics on Cognitive Feature Level. We define average feature hit at k (QH@k) to evaluate the ranking
performance as follows,
QH@k(τ q , τ˜ q) =
∑k
i=1
I(τ˜
q
i ∈ τ
q(1 : k)), (8)
where τ q is the ground-truth ranking list of all the features in all the tasks, τ q(1 : k) is the top k features in the
list, τ˜ q is the predicted ranking list of all the features, and τ˜
q
i is the i-th ranked features in τ˜
q . That is, QH@k
calculates the number of features among top k in the predicted feature lists that are also in the ground truth (i.e.,
hits). Higher QH@k values indicate better prioritization performance.
We define a second evaluation metric weighted average feature hit at k (WQH@k) as follows:
WQH@k(τ q , τ˜ q) =
∑k
j=1
QH@j(τ q , τ˜ q)/k, (9)
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Table 1. Overall Performance in CV
method
parameters feature level task level
d λ QH@5 WQH@5 NH1@1 NH2@1 NH3@1 NH5@1 NHall@1
PLTR
10 - 2.665 3.136 0.605 0.701 0.713 0.725 0.683
10 - 2.647 3.191 0.599 0.677 0.707 0.725 0.677
10 - 2.569 2.957 0.635 0.707 0.689 0.719 0.653
10 - 2.623 3.073 0.623 0.713 0.707 0.719 0.671
50 - 2.467 2.992 0.605 0.695 0.725 0.725 0.653
30 - 2.491 3.080 0.563 0.689 0.713 0.749 0.689
PLTRh
10 - 2.599 3.111 0.623 0.671 0.713 0.719 0.707
10 - 2.575 3.115 0.623 0.677 0.737 0.749 0.695
10 - 2.419 2.827 0.647 0.695 0.671 0.707 0.635
30 - 2.138 2.583 0.629 0.701 0.695 0.695 0.593
50 - 2.102 2.470 0.533 0.677 0.743 0.754 0.629
30 - 2.281 2.768 0.563 0.689 0.707 0.760 0.701
KRL
- 2 2.102 2.167 0.569 0.611 0.635 0.683 0.689
- 1.5 2.078 2.143 0.503 0.575 0.617 0.677 0.760
BMTMKL - - 2.443 2.614 0.413 0.491 0.593 0.784 0.749
The column “d” corresponds to the latent dimension. The best performance of each method is in bold. The best performance under each evaluation metric is underlined
that is, WQH@k is a weighted version of QH@k that calculates the average of QH@j (j = 1, · · · ,k) over top k .
Higher WQH@k indicates more feature hits and those hits are ranked on top in the ranking list.
6.4.2 Metrics on Cognitive Task Level. We use the mean of the top-д normalized ground-truth scores/predicted
scores on the features of each cognitive task for a patient as the score of that task for that patient. For each
patient, we rank the tasks using their ground-truth scores and use the ranking as the ground-truth ranking of
these tasks. Thus, these scores measure how much relevant to AD the task indicates for the patients. We use
the predicted scores to rank cognitive tasks into the predicted ranking of the tasks. We define a third evaluation
metric task hit at k (NHд@k) as follows to evaluate the ranking performance in terms of tasks,
NHд@k(τ
n
д , τ˜
n
д ) =
∑k
i=1
I(τ˜nдi ∈ τ
n
д (1 : k)), (10)
where τnд /τ˜
n
д is the ground-truth/predicted ranking list of all the tasks using top-д question scores.
7 EXPERIMENTAL RESULTS
7.1 Overall Performance on CV
Table 1 presents the performance of PLTR, PLTRh and two baseline methods in the CV setting.
7.1.1 Comparison on cognitive feature level. For cognitive features from all tasks, PLTR is able to identify on
average 2.665 out of the top-5 most relevant ground-truth cognitive features among its top-5 predictions (i.e.,
QH@5=2.665). PLTRh achieves similar performance as PLTR, and identifies on average 2.599most relevant ground-
truth cognitive features on its top-5 predictions (i.e., QH@5=2.599). PLTR and PLTRh significantly outperform
the baseline methods in terms of all the evaluation metrics on cognitive feature level (i.e., QH@5 and WQH@5).
Specifically, PLTR outperforms the best baseline method BMTMKL at 9.1% and 22.1% on QH@5 and WQH@5,
respectively. PLTRh also outperforms BMTMKL at 6.4% and 19.2% on QH@5 and WQH@5, respectively. These
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experimental results demonstrate that among the top 5 features in the ranking list, PLTR and PLTRh are able to
rank more relevant features on top than the two strong baseline methods and the positions of those hits are also
higher than those in the baseline methods.
7.1.2 Comparison on cognitive task level. For the scenario to prioritize cognitive tasks that each patient should
take, PLTR and PLTRh are able to identify the top-1 most relevant task for 72.5% and 74.3% of all the patients when
using 3 features to score cognitive tasks, respectively (i.e., NH3=0.725 for PLTR and NH3=0.743 for PLTRh). This
indicates the strong power of PLTR and PLTRh in prioritizing cognitive features and in recommending relevant
cognition tasks for real clinical applications. We also find that PLTR and PLTRh are able to outperform baseline
methods onmost of themetrics on cognitive task level (i.e., NHд@1). PLTR outperforms the best of baseline meth-
ods BMTMKL at 11.6%, 16.7% and 14.2% on NH1@1, NH2@1 and NH3@1, respectively. PLTRh performs even better
than PLTR on NH1@1 and NH3@1, in addition to that it outperforms the best performance of baseline methods
at 13.7%, 14.7% and 17.0% on NH1@1, NH2@1 and NH3@1, respectively. PLTR and PLTRh perform slightly worse
than baseline methods on NH5@1 and NHall@1 (0.760 vs 0.784 on NH5@1 and 0.707 vs 0.760 on NHall@1). These
experimental results indicate that PLTR and PLTRh are able to push the most relevant task to the top of the rank-
ing list than baseline methods when using a small number of features to score cognitive tasks. Note that in CV,
each patient has only a few cognitive tasks in the testing set. Therefore, we only consider the evaluation at the
top task in the predicted task rankings (i.e., only NHд@1 in Table 1).
Table 1 also shows that PLTRh outperforms PLTR on most of the metrics on cognitive task level (i.e., NHд@1).
PLTRh outperforms PLTR at 1.9%, 2.5%, 1.5% and 2.6% on NH1@1, NH3@1, NH5@1 and NHall@1, respectively.
This indicates that generally PLTRh is better than PLTR on ranking cognitive tasks in CV setting. The reason could
be that the hinge-based loss functions with pre-defined margins can enable significant difference between the
scores of relevant features and irrelevant features, and thus effectively push relevant features upon irrelevant
features.
7.2 Overall Performance on LOV
Table 2 and Table 3 presents the performance of PLTR, PLTRh and two baseline methods in the LOV setting. We
first hold out 26 (Table 2) and 52 (Table 3) AD patients as testing patients, respectively. We determine these hold-
out AD patients as the ones that have more than 10 similar AD patients in the training set with corresponding
patient similarities higher than 0.67 and 0.62, respectively.
7.2.1 Comparison on cognitive feature level. Table 2 and Table 3 show that PLTR and PLTRh significantly out-
perform the baseline methods in terms of all the evaluation metrics on cognitive feature level (i.e., QH@5 and
WQH@5), which is consistent with the experimental results in CV setting. When 26 patients are hold out for
testing, with parameters α = 0.5, β = 1.5, γ = 1.0 and d = 30, PLTR outperforms the best baseline method KRL
at 13.4% and 1.3% on QH@5 and WQH@5, respectively. The performance of PLTRh is very comparable with that
of PLTR " PLTRh outperforms KRL at 13.4% and 0.5% on QH@5 and WQH@5, respectively. When 52 patients are
hold out for testing, with parameters α = 0.5, β = 0.5, γ = 1.0 and d = 50, PLTR outperforms the best baseline
method KRL at 18.1% and 7.8% on QH@5 and WQH@5, respectively. PLTRh even performs better than PLTR in
this setting. In addition, PLTRh outperforms KRL at 19.7% and 9.5% on QH@5 and WQH@5, respectively. These
experimental results demonstrate that for new patients, PLTR and PLTRh are able to rank more relevant features
to the top of the ranking list than the two baseline methods. They also indicate that for new patients, ranking
based methods (e.g., PLTR and PLTRh) are more effective than regression based methods (e.g., KRL and BMTMKL)
for biomarker prioritization.
7.2.2 Comparison on cognitive task level. Table 2 also shows that when 26 patients are hold out for testing, PLTR
and PLTRh are both able to identify the top most relevant questionnaire for 84.6% of the testing patients (i.e.,
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Table 2. Overall Performance in LOV on 26 testing patients
method
feature level task level
QH@5 WQH@5 NH1@1 NH1@5 NH2@1 NH2@5 NH3@1 NH3@5 NH5@1 NH5@5 NHall@1 NHall@5
PLTR
1.615 1.906 0.846 3.231 0.577 3.385 0.231 3.654 0.308 3.346 0.808 3.692
1.500 1.778 0.846 3.269 0.577 3.538 0.269 3.654 0.269 3.269 0.808 3.577
1.538 1.856 0.846 3.192 0.577 3.423 0.308 3.731 0.346 3.346 0.808 3.615
1.577 1.851 0.846 3.192 0.577 3.462 0.308 3.654 0.346 3.462 0.808 3.654
1.615 1.906 0.846 3.231 0.577 3.385 0.231 3.654 0.308 3.346 0.808 3.692
PLTRh
1.615 1.836 0.846 3.192 0.577 3.500 0.269 3.731 0.346 3.731 0.808 4.154
1.538 1.891 0.846 3.192 0.577 3.500 0.269 3.731 0.346 3.615 0.808 4.038
1.538 1.856 0.769 3.308 0.577 3.462 0.269 3.615 0.308 3.385 0.808 3.500
1.538 1.712 0.846 3.115 0.577 3.423 0.154 3.731 0.308 3.808 0.808 4.269
KRL
1.423 1.656 0.615 2.615 0.577 3.308 0.038 3.577 0.346 3.962 0.808 4.269
1.346 1.881 0.577 2.615 0.577 3.308 0.038 3.577 0.346 3.962 0.808 4.269
1.346 1.435 0.808 3.423 0.538 3.500 0.346 3.731 0.154 3.423 0.808 3.538
BMTMKL 0.423 0.212 0.846 2.615 0.577 3.308 0.038 3.577 0.346 3.769 0.808 4.269
The column “n” corresponds to the number of hold-out testing patients. The bset performance of eachmethod is in bold. The best performance under each evaluation
metric is underlined.
22 patients) under NH1@1. Table 3 shows that when 52 patients are hold out for testing, PLTR and PLTRh are
both able to identify for 80.8% of the testing patients (i.e., 42 patients) under NH1@1. Note that the hold-out
testing patients in LOV do not have any cognitive features. Therefore, the performance of PLTR and PLTRh as
above demonstrates their strong capability in identifying most AD related cognitive features based on imaging
features only. We also find that PLTR and PLTRh are able to achieve similar or even better results compared to
baseline methods in terms of the evaluation metrics on cognitive task level (i.e., NHд@1 and NHд@5). When
26 patients are hold out for testing, PLTR and PLTRh outperform the baseline methods in terms of NHд@1 (i.e.,
д = 1, 2 . . . 5). They are only slightly worse than KRL on ranking relevant tasks on their top-5 of predictions
when д = 1 or д = 5 (3.308 vs 3.423 on NH1@5 and 3.808 vs 3.962 on NH5@5). When 52 patients are hold out
for testing, PLTR and PLTRh also achieve the best performance on most of the evaluation metrics. They are only
slightly worse than KRL on NH2@1, NH5@5 (0.423 vs 0.481 on NH2@1 and 3.712 vs 3.808 on NH5@5). These
experimental results demonstrate that among top 5 tasks in the ranking list, PLTR and PLTRh rank more relevant
task on top than KRL.
It’s notable that in Table 2 and Table 3, as the number of features used to score cognitive tasks (i.e., д in
NHд@k) increases, the performance of all the methods in NHд@1 first declines and then increases. This may
indicate that as д increases, irrelevant features which happen to have relatively high scores will be included in
scoring tasks, and thus degrade the model performance on NHд@1. However, generally, the scores of irrelevant
features are considerably lower than those of relevant ones. Thus, as more features are included, the scores for
tasks are more dominated by the scores of relevant features and thus the performance increases.
We also find that BMTMKL performs poorly on NH3@1 in both Table 2 and Table 3. This indicates that BMTMKL,
a regression-based method, could not well rank relevant features and irrelevant features. It’s also notable that
generally the best performance for the 26 testing patients is better than that for 52 testing patients. This may be
due to that the similarities between the 26 testing patients and their top 10 similar training patients are higher
than those for the 52 testing patients. The high similarities enable accurate latent vectors for testing patients.
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Table 3. Overall Performance in LOV on 52 testing patients
method
feature level task level
QH@5 WQH@5 NH1@1 NH1@5 NH2@1 NH2@5 NH3@1 NH3@5 NH5@1 NH5@5 NHall@1 NHall@5
PLTR
1.385 1.668 0.788 3.212 0.423 3.654 0.115 3.750 0.288 3.423 0.788 3.423
1.327 1.616 0.808 3.269 0.423 3.654 0.115 3.731 0.173 3.423 0.788 3.404
1.327 1.652 0.788 3.212 0.423 3.712 0.115 3.750 0.269 3.423 0.788 3.404
1.308 1.616 0.788 3.154 0.423 3.654 0.115 3.712 0.288 3.481 0.788 3.615
1.288 1.581 0.808 3.173 0.423 3.596 0.115 3.750 0.192 3.519 0.788 3.635
1.269 1.616 0.808 3.115 0.423 3.635 0.115 3.731 0.250 3.481 0.788 3.635
PLTRh
1.404 1.656 0.750 2.827 0.404 3.250 0.173 3.481 0.385 3.596 0.788 4.154
1.365 1.695 0.731 2.808 0.365 3.308 0.173 3.462 0.365 3.596 0.788 4.154
1.327 1.562 0.808 3.077 0.404 3.365 0.135 3.577 0.250 3.673 0.788 4.115
1.327 1.605 0.769 3.154 0.385 3.596 0.135 3.712 0.212 3.519 0.788 3.577
1.308 1.609 0.769 2.904 0.385 3.308 0.192 3.442 0.365 3.654 0.788 4.154
1.327 1.605 0.769 3.154 0.385 3.596 0.135 3.712 0.212 3.519 0.788 3.577
1.288 1.545 0.788 3.000 0.404 3.385 0.154 3.558 0.308 3.712 0.788 4.154
KRL
1.173 1.548 0.096 2.577 0.385 3.231 0.077 3.385 0.346 3.808 0.788 4.154
1.173 1.534 0.154 2.615 0.250 3.192 0.077 3.385 0.346 3.712 0.788 4.154
1.096 1.437 0.077 2.577 0.462 3.231 0.077 3.385 0.346 3.808 0.788 4.154
0.423 0.504 0.019 2.019 0.038 2.500 0.115 2.481 0.115 2.712 0.019 2.673
BMTMKL 0.403 0.255 0.808 2.577 0.481 3.231 0.077 3.385 0.346 3.596 0.788 4.154
The column “n” corresponds to the number of hold-out testing patients. The best performance of each model is in bold. The best performance under each evaluation
metric is upon underline.
Table 2 and Table 3 also show that PLTRh is better than PLTR on ranking cognitive tasks in LOV setting. When
26 patients are hold out for testing, PLTRh outperforms PLTR on NH1@5, NH5@5 and NHall@5 and achieves very
comparable performance on the rest metrics. When 52 patients are hold out for testing, PLTRh is able to achieve
better performance than PLTR on QH@5, WQH@5, NH3@1, NH5@1, NH5@5 and NHall@5 and also achieves
very comparable performance on the rest metrics. Generally, PLTRh outperforms PLTR in terms of metrics on cog-
nitive task level. This demonstrates the effectiveness of loss-based methods in separating relevant and irrelevant
features during modeling.
7.3 Case Study
When NH1@1 achieves its optimal performance 0.846 for the 26 testing patients in LOV (i.e., the first row block in
Table 2), the corresponding most common task that is prioritized for the testing patients is Rey Auditory Verbal
Learning Test (RAVLT), including the following cognitive features: 1) trial 1 total number of words recalled; 2)
trial 2 total number of words recalled; 3) trial 3 total number of words recalled; 4) trial 4 total number of words
recalled; 5) trial 5 total number of words recalled; 6) total Score; 7) trial 6 total number of words recalled; 8) list
B total number of words recalled; 9) 30 minute delay total; and 10) 30 minute delay recognition score. This task
is also the most relevant task in the ground truth if tasks are scored correspondingly. RAVLT is a well-known
cognitive test that assesses learning and memory, and has shown promising performance in early detection of
AD [18]. A number of studies have reported high correlations between various RAVLT scores with different brain
regions [3]. For example, RAVLT recall is associated with medial prefrontal cortex and hippocampus; RAVLT
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recognition is highly correlated with thalamic and caudate nuclei. Genetic analysis of APOE ε4 allele, the most
common variant of AD, reported its association with RAVLT score in an early-MCI (EMCI) study [19]. The fact
that RAVLT is prioritized demonstrates the strong power of PLTR in prioritizing cognitive features to assist AD
diagnosis.
Similarly, we find the top-5 most frequent cognitive tasks corresponding to the performance at NH3@5=3.731
for the 26 hold-out testing patients. They are: Functional Assessment Questionnaire (FAQ), Clock Drawing Test
(CDT), Weschler’s Logical Memory Scale (LOGMEM), Rey Auditory Verbal Learning Test (RAVLT), and Neu-
ropsychiatric Inventory Questionnaire (NPIQ). In addition to RAVLT discussed above, other top prioritized cog-
nitive tasks have also been reported to be associated with AD or its progression. In an MCI to AD conversion
study, FAQ, NPIQ and RAVLT showed significant difference between MCI-converter and MCI-stable groups [20].
These evidences further demonstrate the diagnostic power of our method.
8 CONCLUSIONS
We have proposed an innovative machine learning paradigm for prioritizing cognitive assessments according to
their relevance to AD at the individual patient level. The paradigm tailors the cognitive biomarker discovery and
cognitive assessment selection process to the brain morphometric characteristics of each individual patient. It
has been implemented using newly developed learning-to-rank method PLTR and PLTRh. Our empirical study on
the ADNI data has yielded promising results to identify and prioritize individual-specific cognitive biomarkers as
well as cognitive assessment tasks based on the individual’s structural MRI data. In addition, PLTRh shows better
performance than PLTR on ranking cognitive assessment tasks. The resulting top ranked cognitive biomark-
ers and assessment tasks have the potential to aid personalized diagnosis and disease subtyping, and to make
progress towards enabling precision medicine in AD.
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